13,300 Shares in Altimmune, Inc. (NASDAQ:ALT) Bought by PFG Investments LLC

PFG Investments LLC purchased a new position in shares of Altimmune, Inc. (NASDAQ:ALT) in the fourth quarter, HoldingsChannel reports. The fund purchased 13,300 shares of the company’s stock, valued at approximately $96,000.

Several other large investors have also added to or reduced their stakes in ALT. Bellevue Group AG lifted its position in Altimmune by 43.9% during the third quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after purchasing an additional 263,660 shares during the period. Virtu Financial LLC purchased a new position in shares of Altimmune during the 3rd quarter valued at about $674,000. Barclays PLC lifted its holdings in shares of Altimmune by 93.0% in the 3rd quarter. Barclays PLC now owns 155,741 shares of the company’s stock valued at $956,000 after buying an additional 75,064 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Altimmune by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock worth $1,299,000 after buying an additional 4,772 shares during the last quarter. Finally, Stifel Financial Corp grew its holdings in Altimmune by 77.4% during the third quarter. Stifel Financial Corp now owns 17,752 shares of the company’s stock worth $109,000 after acquiring an additional 7,746 shares during the period. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Altimmune Stock Performance

Altimmune stock opened at $6.64 on Friday. The stock has a market capitalization of $472.24 million, a P/E ratio of -4.28 and a beta of 0.22. The company’s fifty day moving average price is $7.78 and its 200 day moving average price is $7.17. Altimmune, Inc. has a 1 year low of $5.28 and a 1 year high of $14.84.

Altimmune (NASDAQ:ALT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.03. The business had revenue of $0.01 million for the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same quarter last year, the business earned ($0.39) EPS. Sell-side analysts predict that Altimmune, Inc. will post -1.35 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. UBS Group started coverage on Altimmune in a report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research note on Wednesday, January 22nd. Finally, Stifel Nicolaus assumed coverage on shares of Altimmune in a research report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target on the stock. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $20.83.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.